Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

• Status: Completed
• Trial end date: 2018-06-02
• Target enrollment: 0
• Participant gender: All

Summary

Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification of prognostic morphological characteristics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Hietzing
• Treatments: Bevacizumab; Endothelial Growth Factors; Pharmaceutical Solutions; Ranibizumab

Criteria

Inclusion criteria:

• DME that will be detected clinically and on FA as well as on SD-OCT [diffuse macular edema with central retinal thickness (CRT) ≥300µm involving the center of the macular area]

• Patients will be included into the present study following informed consent

• Best-corrected-visual-acuity (BCVA) between 0.06 (1.2logMAR) and 0.63 (0.20logMAR).

Exclusion criteria:

• Eyes with other retinal diseases [i.e. age-related macular degeneration (AMD) and associated choroidal neovascularization (CNV), cystoid macular edema (CME) of other origin (e.g. uveitis, Irvine-Gass syndrome, retinal vein occlusion), or retinal dystrophies]